Resistance to first-generation TRK inhibitor therapy in NTRK fusion-positive adult and pediatric cancers conditions next-generation TRK inhibitor activity: a phase I study of selitrectinib

Abstract Purpose: Next-generation TRK inhibitor benefit in NTRK fusion-positive cancers has not been prospectively characterized in relation to the wide variety of first-generation TRK inhibitor resistance mechanisms. Data from the global, multicenter, adult and pediatric phase 1 basket trial of selitrectinib (NCT03215511) was thus analyzed. Experimental design: Eligible patients were aged ≥1 month with any type of solid tumors harboring NTRK fusions. Patients had previously received a TRK inhibitor and progressed on or after, or become intolerant of, this prior therapy, with resistance determined by pre-selitrectinib tumor/plasma sample sequencing. Patients were enrolled in a 3+3 dose-escalation design (aged ≥12 years) or a rolling-6 design (aged <12 years). The primary objective was to determine the maximum-tolerated dose and/or recommended dose for further study. Secondary endpoints included safety, overall response rate (ORR), and pharmacokinetics. Results: Most patients were larotrectinib (70%) or entrectinib (30%) pretreated. Pre-selitrectinib NTRK resistance mutation(s) were identified in 46% of patients. Selitrectinib ORR was highest in on-target only resistance (45%, 95% CI 17–77). Responses were achieved only in solvent-front (e.g., NTRK1 G595R, NTRK3 G623X) and gatekeeper (e.g., NTRK1 F589L, NTRK3 F617X) mutant cancers. MAPK/PI3K pathway alteration-containing cancers did not respond to selitrectinib. Median progression-free survival was worse in MAPK/PI3K alteration-containing cancers (1.8 months, 95% CI 1.6–3.5) than cancers without these alterations (7.0 months, 95% CI 5.3–9.1). Conclusion: Selitrectinib demonstrated antitumor activity after prior TRK inhibition, but this varied according to the resistance mechanism. Thus, molecular characterization of resistance may help inform clinical use of next-generation TRK inhibitors.

Authors

Institutions

Publication Details

Journal
Cancer Research Communications
Published
2026-11-12
DOI
https://doi.org/10.1158/2767-9764.crc-26-0383
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Resistance to first-generation TRK inhibitor therapy in NTRK fusion-positive adult and pediatric cancers conditions next-generation TRK inhibitor activity: a phase I study of selitrectinib

Shivaani Kummar, Noah C. Federman, Martin Højgaard, Víctor Moreno et al.
Cancer Research Communications
Lung Cancer Treatments and Mutations
article

Resistance to first-generation TRK inhibitor therapy in NTRK fusion-positive adult and pediatric cancers conditions next-generation TRK inhibitor activity: a phase I study of selitrectinib

Shivaani Kummar, Noah C. Federman, Martin Højgaard, Víctor Moreno, Esther A. De La Cuesta, David S. Hong, Ahn Eugene, Elena Garralda, Alexander Edward Dela Cruz Drilon, Theodore Willis Laetsch, Jessica J. Lin, Konstantin Lang, Chunlin Chen, Rong Du
article en

Abstract

Abstract Purpose: Next-generation TRK inhibitor benefit in NTRK fusion-positive cancers has not been prospectively characterized in relation to the wide variety of first-generation TRK inhibitor resistance mechanisms. Data from the global, multicenter, adult and pediatric phase 1 basket trial of selitrectinib (NCT03215511) was thus analyzed. Experimental design: Eligible patients were aged ≥1 month with any type of solid tumors harboring NTRK fusions. Patients had previously received a TRK inhibitor and progressed on or after, or become intolerant of, this prior therapy, with resistance determined by pre-selitrectinib tumor/plasma sample sequencing. Patients were enrolled in a 3+3 dose-escalation design (aged ≥12 years) or a rolling-6 design (aged <12 years). The primary objective was to determine the maximum-tolerated dose and/or recommended dose for further study. Secondary endpoints included safety, overall response rate (ORR), and pharmacokinetics. Results: Most patients were larotrectinib (70%) or entrectinib (30%) pretreated. Pre-selitrectinib NTRK resistance mutation(s) were identified in 46% of patients. Selitrectinib ORR was highest in on-target only resistance (45%, 95% CI 17–77). Responses were achieved only in solvent-front (e.g., NTRK1 G595R, NTRK3 G623X) and gatekeeper (e.g., NTRK1 F589L, NTRK3 F617X) mutant cancers. MAPK/PI3K pathway alteration-containing cancers did not respond to selitrectinib. Median progression-free survival was worse in MAPK/PI3K alteration-containing cancers (1.8 months, 95% CI 1.6–3.5) than cancers without these alterations (7.0 months, 95% CI 5.3–9.1). Conclusion: Selitrectinib demonstrated antitumor activity after prior TRK inhibition, but this varied according to the resistance mechanism. Thus, molecular characterization of resistance may help inform clinical use of next-generation TRK inhibitors.

Cancer Research Communications
Hebron University (PS), Memorial Sloan Kettering Cancer Center (US), Children's Hospital of Philadelphia (US), The University of Texas MD Anderson Cancer Center (US), Bayer (United States) (US), University of California, Los Angeles (US), Oregon Health & Science University (US), Loyola University Chicago (US), Rigshospitalet (DK), Vall d'Hebron Institut de Recerca (ES), Vall d'Hebron Hospital Universitari (ES), Hospital Universitario Fundación Jiménez Díaz (ES), Mass General Brigham (US), Bayer (Germany) (DE)
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon